Hovione Strengthens Inhalation Services Portfolio

Loures, Portugal (ots/PRNewswire) -

Hovione announced that a new MG2 Tekna Precision Capsule filling
unit is now online in its Portugal facilities. This investment
reinforces Hovione's Services portfolio in inhalation product
development capabilities (http://www.hovione.com/products-and-service
s/contract-manufacturing-services/drug-product/innovation-and-experti
se), which include proprietary particle engineering technologies as
well as formulation and capsule filling capacity to support from
development to commercial scale projects.

Hovione's new MG2 Tekna Precision Capsule filling unit complements
our offering in encapsulation for inhalation products and has
capacity for up to 110,000 capsules per hour with 100% net weight
check and is fit to process highly potent compounds (down to 30
ng/m3). This unit complements the MG2 Flexalab and Mettler-Toledo
Quantos encapsulation units that allows capsule filling for Phase I
and Phase II clinical trials. In parallel Hovione has installed
capacity in particle engineering suitable for inhalation, namely a
multiple scale Spray Drying units for highly potent compounds, as
well as a new wet polishing suite, and strengthened its analytical
characterization toolbox.

From formulation composition, optimization and precision capsule
filling with 100% fill weight check, to analytical characterization
and scale-up to a commercial scale, Hovione can take product from the
early proof of concept stages up to a fully developed and scaled
process. Together with our API and particle engineering capabilities,
we can fully develop and produce any Inhalation product (http://www.h
ovione.com/products-and-services/contract-manufacturing-services/drug
-product/dry-powder-inhalation-formulation) at Hovione, from API
synthesis to final drug product.

"We are excited to announce this new integrated offering, all at
the same site where our scientists work together in the interface
between particle engineering and final drug product for the benefit
of an optimal product performance. This will allow us to support our
customer's inhalation projects at all scales and contribute to
accelerate drug development and manufacturing timelines," said Filipe
Gaspar, Vice President R&D.

"These investments are driven by significant client demand, since
the market is looking for integrated inhalation product development
solutions that reduce program risk and complexity. Hovione has all
the ingredients for an outstanding partnership starting from clinical
programs and into commercial supply," added Frédéric Kahn, Vice
President Marketing and Sales.

Based on more than 20 years of experience in inhalation, Hovione
can speed up your inhalation drug development, from a very early
stage to a late development stage. Working with Hovione allows
partners to take advantage of cutting edge particle engineering
technologies (http://www.hovione.com/products-and-services/contract-m
anufacturing-services/particle-engineering/technologies) and state of
the art analytical facilities operated by highly skilled and
responsive scientists.

About Hovione

Hovione has over 57 years of experience as a CDMO and is currently
a fully integrated supplier offering from drug substance to drug
product intermediate to drug product. With four FDA inspected sites
in the US, China, Ireland, and Portugal, and development laboratories
in Lisbon and New Jersey, the company provides branded pharmaceutical
customers services for the development and compliant manufacture of
innovative drugs and is able to support highly potent compounds. For
generic pharmaceutical customers the company offers niche off-patent
API products. In the inhalation area Hovione is the only independent
company offering a complete range of services. Please visit
http://www.hovione.com

Contact

Isabel Pina

Director of Corporate Communications

Tel.: 0035121-982-9362

ipina@hovione.com

ots Originaltext: Hovione
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: Hovione, übermittelt durch news aktuell